BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 6,570,000 shares, a growth of 5.1% from the August 31st total of 6,250,000 shares. Based on an average trading volume of 1,290,000 shares, the short-interest ratio is presently 5.1 days.
Insider Transactions at BioMarin Pharmaceutical
In related news, insider Henry J. Fuchs sold 12,000 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $90.43, for a total value of $1,085,160.00. Following the transaction, the insider now owns 176,187 shares of the company’s stock, valued at $15,932,590.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Henry J. Fuchs sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $90.43, for a total value of $1,085,160.00. Following the completion of the transaction, the insider now directly owns 176,187 shares in the company, valued at approximately $15,932,590.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey Robert Ajer sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $90.00, for a total value of $450,000.00. Following the transaction, the executive vice president now directly owns 60,804 shares in the company, valued at $5,472,360. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,000 shares of company stock valued at $2,871,180. Insiders own 1.84% of the company’s stock.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caprock Group LLC lifted its position in BioMarin Pharmaceutical by 6.1% during the 1st quarter. Caprock Group LLC now owns 2,065 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 118 shares during the period. Howe & Rusling Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Howe & Rusling Inc. now owns 36,279 shares of the biotechnology company’s stock valued at $3,755,000 after purchasing an additional 128 shares during the last quarter. Allworth Financial LP boosted its position in shares of BioMarin Pharmaceutical by 57.5% in the 1st quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 130 shares in the last quarter. Integrated Advisors Network LLC grew its stake in shares of BioMarin Pharmaceutical by 4.1% in the 1st quarter. Integrated Advisors Network LLC now owns 3,302 shares of the biotechnology company’s stock worth $321,000 after buying an additional 130 shares during the last quarter. Finally, First Trust Direct Indexing L.P. increased its position in BioMarin Pharmaceutical by 2.3% during the 1st quarter. First Trust Direct Indexing L.P. now owns 5,873 shares of the biotechnology company’s stock valued at $571,000 after buying an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 92.78% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
Shares of BMRN opened at $87.29 on Friday. The company has a 50-day simple moving average of $89.78 and a two-hundred day simple moving average of $91.49. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.94 and a quick ratio of 3.31. The firm has a market capitalization of $16.43 billion, a PE ratio of 167.87 and a beta of 0.36. BioMarin Pharmaceutical has a one year low of $80.53 and a one year high of $117.77.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its earnings results on Monday, July 31st. The biotechnology company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.10. BioMarin Pharmaceutical had a return on equity of 4.03% and a net margin of 4.47%. The company had revenue of $595.28 million during the quarter, compared to analysts’ expectations of $591.46 million. On average, analysts anticipate that BioMarin Pharmaceutical will post 1.25 EPS for the current fiscal year.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- 3 Healthcare Dividend Stocks to Buy
- Huawei Has Entered The Chips Race, Markets Still Prefer These
- Business Services Stocks Investing
- Restaurant Stocks Go on Sale…Which Are Really on the Value Menu?
- Trading Stocks: RSI and Why it’s Useful
- 5 Reasons to Buy and Hold Exxon Mobil For 2024
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
